2 Information about autologous anti-CD19-transduced CD3+ cells
2.3 The price was submitted as commercial in confidence. The company has a commercial arrangement. This makes treatment with autologous anti‑CD19‑transduced CD3+ cells available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.